Why the study?
Does losartan improve cellular apoptosis and signal transduction in rats following acute myocardial infarction?
Does losartan improve cellular apoptosis and signal transduction in rats following acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Losartan exerts cardioprotective effects post-AMI in rats by reducing cellular apoptosis and modulating PKC-epsilon and p38 MAPK signal transduction.
We tested hypothesis that acute myocardial infarction (AMI) induces cellular apoptosis and serial changes of protein kinase C epsilon (PKC-epsilon) and p38 mitogen-activated protein kinase (p38 MAPK), and tested cardio-protective effect of losartan in this condition. The rats were assigned to group A (sacrificed on day 2), group B (sacrificed on day 5), and group C (sacrificed on day 14). Rats in each group were further randomized into the following groups: AMI (ligation of left coronary artery) without losartan (AMI-L0); AMI with losartan 20 mg/ kg/d (AMI-L1); and sham groups (L0 and L1). The PKC-epsilon expression in membrane compartment was increased in AMI-L1 group than in other groups on day 5 and in AMI groups than in sham groups on day 14 (P < .01). Phosphorylated form of cytosolic p38 MAPK level was increased in AMI-L1 than in other groups on day 14 (P < .05). Furthermore, 14-day left ventricular ejection fraction was higher and cellular apoptosis was lower in AMI-L1 group than in AMI-L0 group (P < .0001).
No takes yet. Share an insight, caveat, or question.
Chua et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: